Goldman Sachs Group Inc. increased its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 163.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 645,366 shares of the company's stock after purchasing an additional 400,430 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.52% of 10x Genomics worth $5,634,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the last quarter. Amundi lifted its position in 10x Genomics by 16,013.7% during the 1st quarter. Amundi now owns 320,340 shares of the company's stock worth $2,553,000 after acquiring an additional 318,352 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock valued at $62,016,000 after acquiring an additional 4,987,195 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of 10x Genomics by 35.3% in the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after acquiring an additional 2,657 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of 10x Genomics by 134.4% in the 1st quarter. AQR Capital Management LLC now owns 1,212,429 shares of the company's stock valued at $10,585,000 after acquiring an additional 695,227 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.
Wall Street Analyst Weigh In
TXG has been the subject of a number of analyst reports. Piper Sandler initiated coverage on 10x Genomics in a research report on Thursday, September 11th. They set a "neutral" rating and a $15.00 price objective for the company. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research report on Monday, August 11th. UBS Group boosted their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday, September 13th. Finally, Wall Street Zen lowered 10x Genomics from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, 10x Genomics presently has a consensus rating of "Hold" and a consensus price target of $13.65.
Check Out Our Latest Analysis on 10x Genomics
Insiders Place Their Bets
In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,149 shares of company stock worth $539,865. Corporate insiders own 9.39% of the company's stock.
10x Genomics Stock Down 1.7%
10x Genomics stock traded down $0.23 during trading hours on Friday, hitting $13.04. The stock had a trading volume of 3,262,793 shares, compared to its average volume of 2,167,720. The company has a market cap of $1.62 billion, a PE ratio of -18.63 and a beta of 2.00. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $23.53. The company has a 50-day moving average of $13.29 and a two-hundred day moving average of $10.90.
10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.
10x Genomics Profile
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Further Reading
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
